Clinical trial

A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

NCT06198751

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2024-02-05

PhasePHASE2

Study timeline

Study start (actual)2024-02-05Date precision: day

Registry last updated2025-08-19

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Interventions

6.0 mg/kg of TQB2102 for injectionDRUG

7.5 mg/kg of TQB2102 for injectionDRUG

Sponsors & collaborators

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.lead sponsor

Mapped research locations

ShanghaiShanghai Municipality, China1 ChangshaHunan, China1 ShenyangLiaoning, China1 ChongqingChongqing Municipality, China1 FuzhouFujian, China1 HarbinHeilongjiang, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06198751 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.